(59 days)
Not Found
No
The device description focuses on the physical components, gas expansion for cooling, and a nerve stimulator. There is no mention of AI, ML, or any software that would suggest learning or adaptive capabilities.
Yes
The device is intended for use in blocking pain by temporarily ablating peripheral nerves, which is a therapeutic intervention.
No
The device is a therapeutic device intended for pain management by temporarily ablating peripheral nerves. While it includes a nerve stimulator to locate nerves (a diagnostic-like function), its primary purpose as stated in the "Intended Use" is to block pain, making it a treatment, not a diagnostic tool.
No
The device description clearly outlines multiple hardware components including cryoprobes, a console, a footswitch, and gas tanks. It describes the physical mechanism of action (Joule-Thompson effect) and the hardware involved in delivering the cryotherapy.
Based on the provided information, the CryoStar™ System is not an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use is to "block pain by temporarily ablating the peripheral nerves." This is a therapeutic intervention performed directly on the patient's body.
- Device Description: The device description details a system that physically interacts with the patient's nerves using cryoablation. It involves probes, a console for gas control and nerve location, and a footswitch.
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body (like blood, urine, tissue) to provide information about a person's health. The CryoStar™ System does not perform any such tests on samples.
The CryoStar™ System is a therapeutic medical device used for pain management through cryoablation of peripheral nerves.
N/A
Intended Use / Indications for Use
The CryoStar™ system is a cryoanalgesia device intended for use in blocking pain by temporarily ablating the peripheral nerves.
Product codes
GXI, GXH
Device Description
The CryoStar™ system consists of a range of cryoprobes that are used for freezing nerves to block pain by temporary ablation. A console is used to house and control the supply of gas to the cryoprobe and to provide an electrical nerve location device. A footswitch completes the system. A convenience procedure kit for probe placement is also provided as a single use disposable.
In the CryoStar™ system, compressed nitrous oxide or carbon dioxide is directed to the tip of the cryoprobe where it is allowed to expand through a fine annular space. The expansion of the gas to near atmospheric pressure causes cooling by the Jouie Thompson effect. The design of the cryoprobes is such that the warmer incoming gas maintains the outer stem of the cryoprobe above freezing temperatures to prevent freezing up the stem of the cryoprobe and unwanted tissue damage. A peripheral nerve stimulator in the CryoStar™ console facilitates the location of the peripheral nerve prior to freezing. Freezing of the nerve fibers creates a block which prevents the conduction of pain. The effect is usually non-permanent, and a repeat of the treatment may be necessary to deal with long term pain.
The CryoStar™ console has been designed to provide a simple user interface, together with a series of error detection and warning systems to ensure proper operation. The pedestal of the console provides a convenient small footprint mobile base for the system, and houses up to four gas tanks. A simple footswitch completes the system.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
peripheral nerves
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 882.4250 Cryogenic surgical device.
(a)
Identification. A cryogenic surgical device is a device used to destroy nervous tissue or produce lesions in nervous tissue by the application of extreme cold to the selected site.(b)
Classification. Class II (performance standards).
0
lof 2 K031482
2
JUL 1 0 2003
510(k) Summary
June 4" 2003
1 Submitter
Cryomedical Instruments Itd Cryomed House Grove Way Mansfield Woodhouse Mansficid Nottinghamshirc NG19 8BW United Kingdom
Mr. Gareth Copping, Technical Director Contact Person: +44 1623 424200 Tel: +44 1623 424777 Hax: E-mail: gareth.copping@cryomed.co.uk
2 Name of Device
| Proprietary Name: | CryoStar™ system, comprising:
a) CryoStar™ console
b) CryoStar™ 1mm cryoprobe
d) CryoStar™ 2mm cryoprobe
c) Convenience procedure kit for probe placement |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Common Name: | Cryoanalgesia System |
| Device Classification: | Cryogenic surgical devices have been placed in Class II as per
21 CFR Regulation Number 882.4250 and assigned the
Product Code GXI |
3 Predicate Devices
The components of the CryoStar™ system are substantially equivalent to the following legally marketed devices:
| K781302 | Spembly Lloyd Neurostat |
|---|---|
| K831963 | Cryomedics Neurostat |
| K854334 | Wallach Painblocker WA5000 |
This statement is based on the similarity of the subject device to the predicate devices in intended use, materials, design and principles of operation.
1
KO31482
4 Device Description
The CryoStar™ system consists of a range of cryoprobes that are used for freezing nerves to block pain by temporary ablation. A console is used to house and control the supply of gas to the cryoprobe and to provide an electrical nerve location device. A footswitch completes the system. A convenience procedure kit for probe placement is also provided as a single use disposable.
In the CryoStar™ system, compressed nitrous oxide or carbon dioxide is directed to the tip of the cryoprobe where it is allowed to expand through a fine annular space. The expansion of the gas to near atmospheric pressure causes cooling by the loule Thompson effect. The design of the cryoprobes is such that the warmer incoming gas maintains the outer stem of the cryoprobe above freezing temperatures to prevent freezing up the stem of the cryoprobe and unwanted tissue damage. A peripheral nerve stimulator in the CryoStar™ console facilitates the location of the peripheral nerve prior to freezing. Freezing of the nerve fibers creates a block which prevents the conduction of pain. The effect is usually non-permanent, and a repeat of the treatment may be necessary to deal with long term pain.
The CryoStar™ console has been designed to provide a simple user interface, together with a series of error detection and warning systems to ensure proper operation. The pedestal of the console provides a convenient small footprint mobile base for the system, and houses up to four gas tanks. A simple footswitch completes the system.
Intended Use 5
The CryoStar™ system is a cryoanalgesia device intended for use in blocking pain by temporatily ablating the peripheral nerves.
Summary of Substantial Equivalence 6
The CryoStar™ system is similar in design, intended use and performance characteristics to the predicate devices. There are now new issues of safety of effectiveness raised by the subject device.
2
Image /page/2/Picture/12 description: The image shows the seal of the Department of Health & Human Services USA. The seal is circular, with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or other bird with three wavy lines above it. The image is in black and white.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JUL 1 0 2003
Mr. Gareth Copping Technical Director Cryomedical Instruments Ltd Cryomed House Grove Way Mansfield Woodhouse Mansfield Nottinghamshire United Kingdom NG19 8BW
Re: K031482
Trade/Device Name: CryoStar™ Cryoanalgesia System Regulation Number: 21 CFR 882.4250 Regulation Name: Cryogenic surgical device Regulatory Class: II Product Code: GXH Dated: June 10, 2003 Received: June 25, 2003
Dear Mr. Copping:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 - Mr. Gareth Copping
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Miriam C. Provost
Ca Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use Statement
Ver/ 3 - 4/24/96
Applicant: Cryomedical Instruments Ltd
510(k) Number (if known): K031482
Device Name: CryoStar™ Cryoanalgesia System
Indications For Use:
The CryoStar™ System is a cryoanalgesia device intended for use in blocking pain by
temporarily ablating the peripheral nerves.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE
IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE):
(Per 21 CFR 801.109)
(Optional Format 1-2-96)
Miriam C. Provost
ion Sign-Off) sion of General, Restorative and Neurological Devices
510(k) Number K031482